We develop lock antibodies for safer therapy
Besides providing platform service, Precisemab also utilizes antibody lock technology to develop potential Lock-antibody products in the area of autoimmune disease, surface marker, immunotherapy and antibody drug conjugate.
Applications
EGFR
PSM101
EGFR-directed tumor-activated monoclonal antibody
PSM101 is a tumor-activated anti-EGFR monoclonal antibody developed using PrecisemAb’s proprietary Antibody Lock Technology.The molecule is designed to remain inactive in circulation and become selectively activated within the tumor microenvironment, enabling precise targeting of EGFR-expressing tumor cells while sparing normal tissues.
This selective activation mechanism expands the therapeutic window for anti-EGFR therapies and significantly reduces systemic toxicity compared to conventional antibodies.PSM101 is currently in preclinical evaluation and demonstrates strong tumor-selective activity and favorable pharmacokinetic properties in animal models.
TNF-α、IL-1β
PSM915
Tumor-selective immune modulating antibody
PSM915 is a conditionally activated immune-modulating antibody created through the Antibody Lock platform to achieve disease-restricted immune activation. It is designed to engage and activate immune effector pathways only within pathological tissues, minimizing systemic immune-related adverse events.
Precisemab has demonstrated in autoimmune disease models that conditionally activated antibodies can effectively suppress excessive inflammatory responses while preserving normal immune function. These studies confirmed that immune activation occurs selectively within disease lesions, resulting in meaningful therapeutic improvement with significantly reduced systemic toxicity.
PD-1、CTLA-4
4-1BB、CD28、CD47
Lock BsAb
Tumor-activated bispecific antibody platform
Lock BsAb is a bispecific antibody developed using Precisemab’s Antibody Lock Technology, designed to enable tumor-selective activation of either or both binding arms.The molecule remains functionally masked in systemic circulation and becomes activated only within the tumor microenvironment, ensuring highly specific target engagement while minimizing binding to normal tissues.
Precisemab has successfully established an early T-cell engager (TCE) bispecific design, which has demonstrated therapeutic efficacy in preclinical tumor models.This approach represents a versatile and safer bispecific antibody platform for future oncology applications, combining precise tumor targeting with effective immune activation.
TBD
(To be determined)
Lock ADC
Tumor-selective antibody-drug conjugate
Lock ADC integrates PrecisemAb’s Antibody Lock mechanism into a next-generation antibody-drug conjugate (ADC) format.The design confines payload release to tumor-associated protease environments, ensuring that cytotoxic activity occurs only within tumor tissue while maintaining an inactive state in normal organs.
This selective activation significantly enhances tumor specificity and widens the therapeutic window compared to conventional ADCs.Lock ADC demonstrates strong potential to deliver high efficacy with reduced off-target toxicity, establishing a safer path forward for systemic ADC therapy.
